Anthropometric measurements of children with neurofibromatosis type I: impact of plexiform neurofibroma volume and treatment

被引:1
|
作者
Lemberg, Kathryn M. [1 ,2 ]
Gross, Andrea M. [2 ]
Sproule, Lauren M. [3 ]
Liewehr, David J. [4 ]
Dombi, Eva [2 ]
Baldwin, Andrea [5 ]
Steinberg, Seth M. [4 ]
Bornhorst, Miriam [6 ,7 ]
Lodish, Maya [8 ]
Blakeley, Jaishri O. [9 ]
Widemann, Brigitte C. [2 ]
机构
[1] Johns Hopkins Sch Med, Dept Oncol, Baltimore, MD 21205 USA
[2] Ctr Canc Res, Pediat Oncol Branch, Bethesda, MD 20892 USA
[3] McGill Univ, Montreal, PQ, Canada
[4] Ctr Canc Res, Biostat & Data Management Sect, Bethesda, MD USA
[5] Frederick Natl Lab Canc Res, Clin Res Directorate, Frederick, MD USA
[6] Childrens Natl Hosp, Gilbert Family Neurofibromatosis Inst, Washington, DC USA
[7] Ann & Robert H Lurie Childrens Hosp Chicago, Ctr Canc & Blood Disorders, Chicago, IL USA
[8] Univ Calif San Francisco, Div Pediat Endocrinol, San Francisco, CA USA
[9] Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD USA
基金
美国国家卫生研究院;
关键词
GROWTH; PUBERTY; ADULTS; FAMILY; AGE;
D O I
10.1038/s41390-024-03474-z
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
BACKGROUND: In children and adolescents/young adults (CAYA) with neurofibromatosis type I (NF1), associations between anthropometric measurements, plexiform neurofibroma (pNF) tumor volume (TV), and treatment history are unknown. METHODS: We retrospectively investigated anthropometrics in CAYA on the National Cancer Institute (NCI) NF1 Natural History Study who had pNF TV assessed by imaging (n = 106). We determined CDC height/weight percentiles and estimated Preece-Baines (PB) height growth curve parameters. We evaluated variables that could impact height/weight including: (1) pNF volume, (2) pNF directed therapy, and (3) serum IGF-1. RESULTS: 23% of males and 20% of females had height <5th percentile; 13% of males had weight <5th percentile. Estimated median final adult height for males was 171.6 cm (CDC 23rd percentile) and for females was 156.2 cm (CDC 14th percentile). Inverse associations between height and weight percentiles and pNF volume were observed (Spearman's r = -0.277, -0.216, respectively). Estimated median final height was not meaningfully affected by patients who received pNF-directed treatment with MEK inhibitor. 52% of low serum IGF-1 measurements were concurrent with a height percentile <5th. CONCLUSIONS: Greater than expected percentages of patients had height/weight <5th percentile, and median final adult heights were <CDC 25th percentile. pNF volume was inversely associated with height/weight percentiles.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Oral Manifestations of Neurofibromatosis Type 1 in Children with Facial Plexiform Neurofibroma: Report of Three Cases
    Cunha, K. S.
    Rozza-de-Menezes, R. E.
    Andrade, R. M.
    Almeida, L. M. S.
    Janini, M. E. R.
    Geller, M.
    JOURNAL OF CLINICAL PEDIATRIC DENTISTRY, 2015, 39 (02) : 168 - 171
  • [32] Retrospective Cohort Analysis of the Impact of Puberty on Plexiform Neurofibroma Growth in Patients with Neurofibromatosis Type 1
    Kotch, Chelsea
    Dombi, Eva
    Shah, Amish C.
    Smith, Katherine
    Brown, Symone
    Li, Yimei
    Widemann, Brigitte C.
    Fisher, Michael J.
    JOURNAL OF PEDIATRICS, 2023, 260 : 1 - 8
  • [33] Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1
    Gross, Andrea M.
    Singh, Gurbani
    Akshintala, Srivandana
    Baldwin, Andrea
    Dombi, Eva
    Ukwuani, Somto
    Goodwin, Anne
    Liewehr, David J.
    Steinberg, Seth M.
    Widemann, Brigitte C.
    NEURO-ONCOLOGY, 2018, 20 (12) : 1643 - 1651
  • [34] Radiosurgical treatment of ulnar plexiform neurofibroma in a neurofibromatosis type 1 (NF1) patient
    Marcello Marchetti
    Angelo Franzini
    Vittoria Nazzi
    Elena De Martin
    Laura Fariselli
    Acta Neurochirurgica, 2013, 155 : 553 - 555
  • [35] Radiosurgical treatment of ulnar plexiform neurofibroma in a neurofibromatosis type 1 (NF1) patient
    Marchetti, Marcello
    Franzini, Angelo
    Nazzi, Vittoria
    De Martin, Elena
    Fariselli, Laura
    ACTA NEUROCHIRURGICA, 2013, 155 (03) : 553 - 555
  • [36] Neurofibromatosis Type 1 with a Giant Diffuse Plexiform Neurofibroma Invading the Liver
    Yokogawa, Yuko
    Suzuki, Tomohiro
    Suzuki, Hiroyuki
    Nemoto, Rena
    Shimizu, Hiroshi
    Ueda, Tsuyoshi
    Uchihara, Daiki
    Okubo, Yoshinori
    Ichii, Osamu
    Tai, Mayumi
    Ejiri, Yutaka
    Harada, Masaru
    INTERNAL MEDICINE, 2023, 62 (20) : 2971 - 2975
  • [37] A phase I study of thalidomide for the treatment of plexiform neurofibroma in patients with neurofibromatosis 1 (NF1)
    Gupta, A
    Cohen, BH
    Ruggieri, P
    Packer, RJ
    Phillips, P
    NEUROLOGY, 2000, 54 (07) : A12 - A13
  • [38] A rare case of plexiform neurofibroma of the liver in a patient without neurofibromatosis type 1
    Hiroko Nebiki
    Shinsuke Hiramatsu
    Yuhei Sakata
    Takehisa Suekane
    Tomoaki Yamasaki
    Takashi Nakai
    Yoichi Koda
    Akishige Kanazawa
    Takeshi Inoue
    Clinical Journal of Gastroenterology, 2020, 13 : 1297 - 1302
  • [39] Solitary plexiform neurofibroma of the tongue: report of a case with no evidence of neurofibromatosis type 1
    Zhang, Y.
    Chen, M. W. J.
    Petersson, F.
    Lima, A. A. T.
    INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2023, 52 (12) : 1246 - 1249
  • [40] Plexiform neurofibroma in the hepatic hilum associated with neurofibromatosis type 1: case report
    Hoshimoto, Sojun
    Morise, Zenichi
    Takeura, Chinatsu
    Ikeda, Masahiro
    Kagawa, Tadashi
    Tanahashi, Yoshinao
    Okabe, Yasuhiro
    Mizoguchi, Yoshikazu
    Sugioka, Atsushi
    RARE TUMORS, 2009, 1 (01) : 44 - 46